drugIndia
Cart
Already at best price
Glimisave M2 750 Tablet PR

Glimisave M2 750 Tablet PR

Metformin (750mg) + Glimepiride (2mg)

Eris Lifesciences Ltd
150.50188.1320% OFF
In Stock
1
Safe & Secure
Easy Returns
24/7 Support
Delivery
150.5020% OFF
188.13

About This Medicine

Product description & overview

Glimisave M2 750 Tablet PR: A Powerful Combination for Diabetes Management

Glimisave M2 750 Tablet PR is a once-daily oral combination medication containing Glimepiride (2mg) and Metformin (750mg). This unique formulation offers targeted blood sugar control for adults with Type 2 diabetes.

Glimepiride acts on the pancreas to stimulate insulin release, while Metformin works by lowering glucose production in the liver and improving cellular sensitivity to insulin. Together they create a comprehensive approach to managing blood sugar levels.

Glimisave M2 750 Tablet PR is formulated for convenience with a single dose taken once daily before meals. It's important to consult your healthcare professional for personalized dosage recommendations, as individual needs may vary.

Please note: This medication should be used only under the guidance of a qualified healthcare provider. Self-treatment can pose risks and may exacerbate existing conditions. Always prioritize safety and adhere to medical advice.

Active composition

Metformin 750 mg

+1 more active ingredient

About Metformin

Metformin is an oral antihyperglycemic agent used to manage type 2 diabetes mellitus. It works by decreasing glucose production in the liver and improving insulin sensitivity. Metformin is effective in controlling blood sugar levels and preventing diabetes-related complications. In summary, Metformin is vital for managing type 2 diabetes.

How It Works

Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.

Medicine Strength
750 mg

All Active Ingredients

Metformin750 mg
Glimepiride2 mg

Glimepiride

Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.

Dosage & How to Use

Dosage information not available. Please consult your doctor or pharmacist.

Safety Advice

Important precautions

Side Effect Occurrence

Based on clinical trials and patient reports.

Overall Tolerance

Most patients tolerate well

Only 2.3% reported effects

Common Side Effects

Headache8%
Nausea5%
Dizziness3%
Fatigue2%
Rash1%
Higher
Lower

Safety Advice

Alcohol

It is unsafe to consume alcohol with Glimisave M2 750 Tablet PR.

High Risk

Pregnancy

Glimisave M2 750 Tablet PR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Medical Advice

Driving

Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.

Exercise Caution

Liver

Glimisave M2 750 Tablet PR should be used with caution in patients with liver disease. Dose adjustment of Glimisave M2 750 Tablet PR may be needed. Please consult your doctor. Glimisave M2 750 Tablet PR is generally started with a low dose in patients with mild to moderate liver disease, and its use is not recommended in patients with severe liver disease.

Regular Checkup

Breastfeeding

Glimisave M2 750 Tablet PR is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.

Consult Doctor

Kidney

Glimisave M2 750 Tablet PR should be used with caution in patients with kidney disease. Dose adjustment of Glimisave M2 750 Tablet PR may be needed. Please consult your doctor. Use of Glimisave M2 750 Tablet PR is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function tests is advisable while you are taking this medicine.

Regular Checkup

Customer Reviews

0 reviews for Glimisave M2 750 Tablet PR